Skip Navigation LinksHome > April 2015 - Volume 37 - Issue 3 > Single-institution Experience of Unrelated Cord Blood Transp...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0000000000000232
Online Articles: Clinical and Laboratory Observations

Single-institution Experience of Unrelated Cord Blood Transplantation for Primary Immunodeficiency

Chang, Tsung-Yun MD*; Jaing, Tang-Her MD*; Lee, Wei-I MD; Chen, Shih-Hsiang MD*; Yang, Chao-Ping MD*; Hung, Iou-Jih MD*

Collapse Box


Pediatric patients with primary immunodeficiencies (PID) constitute life-threatening medical emergencies. In the absence of an HLA-identical hematopoietic stem cell donor, unrelated donor cord blood transplantation (CBT) is another treatment option. There are little data regarding the outcome of unrelated CBT for PID in Taiwan. We report the results of CBT performed in 8 patients with PID between 2004 and 2013 at Chang Gung Memorial Hospital. The cases included severe combined immunodeficiency (n=4), chronic granulomatous disease (n=2), Wiskott-Aldrich syndrome (n=1), and T-cell immunodeficiency (n=1). Median follow-up time was 73 months. Most UCB recipients received a myeloablative conditioning regimen. There were 7 boys and 1 girl with a median age of 2.5 months at diagnosis (range, antenatal to 17 mo). Median age at transplant was 5.5 months (range, 2 to 74 mo). All but 1 patients engrafted at a median time of 14 days. One developed significant grade III graft-versus-host disease after transplant. Our data show that unrelated CBT in PID is possible. However, no definite conclusions can be drawn from this small number of patients, and more studies are needed to further investigate and confirm these findings.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.


Article Tools


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.